A recent study compared three clinical criteria for rheumatoid arthritis (RA) in patients using certolizumab, assessing the predictability of treatment non-response. Researchers found Clinical Disease Activity Index measurement at three months may predict patient outcomes at 12 months…
![](https://www.the-rheumatologist.org/wp-content/uploads/2016/09/Shutterstock_Generic_RA_500x270-150x150.jpg)